Evidence map›Paper›PMID 40467930›Full record

ArticleEuropean journal of human genetics : EJHG2025

Novel HSPB8 mutations in severe early-onset myopathy with involvement of respiratory and cardiac muscles cause proteostasis defects in cell models.

Barbara Tedesco, Stojan Peric, Goknur Selen Kocak, Jiayan Tan, Han Duong, Ana Töpf, Vidosava Rakocevic-Stojanovic, Sanja Milenkovic, Yolande Parkhurst, Liliane Gibbs and 13 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Genomic medicine in full bloom: a summer farewell issue.European journal of human genetics : EJHG · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Barbara Tedesco *Laboratory of Experimental Biology, Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti" (DiSFeB), Dipartimento di Eccellenza 2018-2027, Università degli Studi di Milano, Milan, Italy.ORCID 0000-0002-7077-3696
Stojan Peric *University of Belgrade, Faculty of Medicine, University Clinical Center of Serbia - Neurology Clinic, Belgrade, Serbia.
Goknur Selen Kocak *John Walton Muscular Dystrophy Research Centre, Institute of Translational and Clinical Research, Newcastle University and Newcastle Hospitals NHS Foundation Trust, International Centre for Life, Newcastle upon Tyne, UK.ORCID 0000-0001-6947-6347
Jiayan Tan *Department of Pediatrics, University of California Irvine, Irvine, CA, USA.ORCID 0009-0005-8336-759X
Han Duong *Department of Pediatrics, University of California Irvine, Irvine, CA, USA.
Ana TöpfJohn Walton Muscular Dystrophy Research Centre, Institute of Translational and Clinical Research, Newcastle University and Newcastle Hospitals NHS Foundation Trust, International Centre for Life, Newcastle upon Tyne, UK.ORCID 0000-0002-9227-2526
Vidosava Rakocevic-StojanovicUniversity of Belgrade, Faculty of Medicine, University Clinical Center of Serbia - Neurology Clinic, Belgrade, Serbia.
Sanja MilenkovicNational Laboratory for Neuromuscular Biopsies, Clinical Hospital Center Zemun, Belgrade, Serbia.
Yolande ParkhurstMuscle Immunoanalysis Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
Liliane GibbsPediatric Radiology, Department of Radiology, University of California Irvine, Irvine, CA, USA.
Angela Martin-RiosDepartment of Pediatrics, University of California Irvine, Irvine, CA, USA.
Pier D LambiaseUniversity College London, Barts Heart Centre, London, UK.
Oliver P GuttmannUniversity College London, Barts Heart Centre, London, UK.
Chiara Marini-BettoloJohn Walton Muscular Dystrophy Research Centre, Institute of Translational and Clinical Research, Newcastle University and Newcastle Hospitals NHS Foundation Trust, International Centre for Life, Newcastle upon Tyne, UK.
Elizabeth HarrisJohn Walton Muscular Dystrophy Research Centre, Institute of Translational and Clinical Research, Newcastle University and Newcastle Hospitals NHS Foundation Trust, International Centre for Life, Newcastle upon Tyne, UK.
Matthew B HarmsDepartment of Neurology, Columbia University Medical Center, New York, NY, USA.
Vukan IvanovicUniversity of Belgrade, Faculty of Medicine, University Clinical Center of Serbia - Neurology Clinic, Belgrade, Serbia.
Veronica MarchesiLaboratory of Experimental Biology, Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti" (DiSFeB), Dipartimento di Eccellenza 2018-2027, Università degli Studi di Milano, Milan, Italy.ORCID 0009-0009-8485-1032
Margherita MiloneDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Vincent TimmermanPeripheral Neuropathy Research Group, Department of Biomedical Sciences and Institute Born Bunge, University of Antwerp, Antwerpen, Belgium.ORCID 0000-0002-2162-0933
Volker StraubJohn Walton Muscular Dystrophy Research Centre, Institute of Translational and Clinical Research, Newcastle University and Newcastle Hospitals NHS Foundation Trust, International Centre for Life, Newcastle upon Tyne, UK.ORCID 0000-0001-9046-3540
Angelo PolettiLaboratory of Experimental Biology, Dipartimento di Scienze Farmacologiche e Biomolecolari "Rodolfo Paoletti" (DiSFeB), Dipartimento di Eccellenza 2018-2027, Università degli Studi di Milano, Milan, Italy. angelo.poletti@unimi.it.ORCID 0000-0002-8883-0468
Virginia KimonisDepartment of Pediatrics, University of California Irvine, Irvine, CA, USA. vkimonis@uci.edu.ORCID 0000-0003-1567-4449

Funding

AFM-Téléthon (French Muscular Dystrophy Association) 23236EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) Solve-RDFondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica (Italian Research Foundation for ALS) MLOpathyFondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica (Italian Research Foundation for ALS) Target-RANFondazione Telethon (Telethon Foundation) GGP19128Fonds Wetenschappelijk Onderzoek (Research Foundation Flanders) FWO-Flanders, n. G040821NMinistero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) PRIN-Progetti di ricerca di interesse nazionale n. 2017F2A2C5Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) PRIN-Progetti di ricerca di interesse nazionale n. 2022EFLFL8Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) Progetto Dipartimenti di Eccellenza to DiSFeBMinistry of Health, Italy | Agenzia Italiana del Farmaco, Ministero della Salute (Italian Medicines Agency) Co_ALSUniversiteit Antwerpen (University of Antwerp) µNEURO Center of Excellence
6 · The paper itself

Abstract

Heat shock protein family B (small) member 8 (HSPB8) promotes chaperone-assisted selective autophagy (CASA), which assures proteostasis in muscles and neurons. HSPB8 frameshift mutations found in neuromyopathies are translated on the same frame, generating the same C-terminal extension, which causes HSPB8 aggregation and proteostasis defects. Here, we describe three novel HSPB8 frameshift variants, translated to protein using the third alternative frame to stop codons downstream to the canonical one and to the one used by other known HSPB8 frameshift mutants. Therefore, these variants are predicted to encode a C-terminal extension that is different in length and amino acids. HSPB8 c.562delC and c.520_523delTACT were identified in two unrelated sporadic patients, while c.515delC, in a familial case of early-onset myopathy. Patients may differentially exhibit additional pathological features, such as neuropathy, respiratory insufficiency, and, remarkably, severe cardiomyopathy. Skeletal muscle biopsies revealed variations in fiber size, atrophy, multiple vacuoles, fat infiltration, and eosinophilic inclusions. In a reconstituted cell model of disease the expression of one representative novel HSPB8 mutant results in i) aggregation of the HSPB8 mutant, ii) sequestration of both the HSPB8 wild-type and CASA complex members, as well as iii) the autophagy receptor sequestosome-1 (SQSTM1/p62), iv) accumulation of ubiquitinated substrates, and v) defects in CASA-mediated degradation. Our results prove that the last exon of the HSPB8 gene is highly susceptible to pathogenic mutations, resulting in a wider phenotypic spectrum associated with HSPB8 frameshift variants. Our studies suggest the importance of HSPB8 genetic testing not only for neuropathy and myopathy but also for cardiomyopathy.

Indexed as

Frameshift MutationHeat-Shock ProteinsMuscular DiseasesProteostasisFemaleHumansMaleMolecular ChaperonesMuscle, SkeletalMyocardiumHeat-Shock ProteinsHSPB8 protein, humanMolecular Chaperones

Identifiers

PMID40467930
PMCPMC12322164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.